News
STAA
24.55
-2.62%
-0.66
STAAR Surgical Earnings Call Highlights Growth and Risks
TipRanks · 4d ago
STAAR Surgical: Buy Rating Maintained as Strong Revenue Growth and Supply Recovery Support $32 Price Target
TipRanks · 4d ago
Staar Surgical price target raised to $34 from $31 at Stifel
TipRanks · 4d ago
At a glance: stocks gapping up premarket
Seeking Alpha · 4d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 4d ago
Staar Surgical Q3 2026 Earnings Call Transcript
Benzinga · 5d ago
STAAR Surgical Announces $50M Buyback Plan
Benzinga · 5d ago
STAAR Surgical Reports Third-Quarter 2026 Financial Results
TipRanks · 5d ago
Staar Surgical reports Q3 adjusted EPS 28c, consensus 17c
TipRanks · 5d ago
STAAR Surgical Non-GAAP EPS of $0.28 beats by $0.11, revenue of $83.4M beats by $4.67M
Seeking Alpha · 5d ago
Staar Surgical Q3 EPS $0.11 Beats $0.05 Estimate, Sales $83.411M Beat $78.762M Estimate
Benzinga · 5d ago
Press Release: STAAR Surgical Reports Third Quarter 2026 Results
Dow Jones · 5d ago
Press Release: STAAR Surgical Reports Third -4-
Dow Jones · 5d ago
*Staar Surgical 3Q Net $5.58M >STAA
Dow Jones · 5d ago
*Staar Surgical 3Q Sales $83.4M >STAA
Dow Jones · 5d ago
*Staar Surgical 3Q EPS 11c >STAA
Dow Jones · 5d ago
STAAR Surgical (NASDAQ:STAA) reports strong Q3 2026
Barchart · 5d ago
STAAR Surgical, Integra LifeSciences, Envista, LeMaitre, and Inspire Medical Systems stocks trade up, what you need to know
Barchart · 5d ago
Weekly Report: what happened at STAA last week (1026-1030)?
Weekly Report · 11/02 10:21
Staar Surgical appoints Pascal Aeschlimann as VP, Asia Pacific
TipRanks · 10/29 11:51
More
Webull provides a variety of real-time STAA stock news. You can receive the latest news about Staar Surg through multiple platforms. This information may help you make smarter investment decisions.
About STAA
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also markets and sells an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company's principal products are ICLs used in refractive surgery, including its EVO family of lenses.